LearnGlossaryMarketStocksSuperinvestorsSign in

BEAM

Beam Therapeutics Inc.

Healthcare · $2.5B market cap

Verdict

We can't put a fair value on BEAM right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-0.7% a year✗
Sales growth22.7% a year✓
Free cash flow growth—?
Return on invested capital-28.6%✗

Follow BEAM

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Beam Therapeutics Inc.

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works